| Similar Articles |
|---|
 |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion.   |
Chemistry World
June 23, 2014
Phillip Broadwith |
Shire fends off AbbVie takeover bid Shire is the latest pharmaceutical company to be targeted for a multi-billion dollar takeover deal from a firm looking to transfer its tax residence outside the US. |
Chemistry World
October 8, 2014
Rebecca Trager |
US tax changes ripple into merger deals The tightened tax rules are pressuring pharmaceutical and medical devices companies to reconsider deals announced recently, according to financial analysts. |
Chemistry World
August 10, 2015
Rebecca Trager |
Shire makes hostile bid for Baxalta Baxalta rejected Shire's initial private offer in July 2015, and the same outcome appears likely this time around. |
Chemistry World
November 11, 2013
Phillip Broadwith |
Shire will cut UK R&D to focus on rare diseases Shire Pharmaceuticals has begun an employee consultation process as it seeks to discontinue a significant proportion of research and development activities at its historic UK base in Basingstoke. |
The Motley Fool
October 30, 2006
Brian Lawler |
Building a Future Shire ADHD drugs are big for Shire now, but the long term isn't as clear. Investors, take note. |
Reason
Aug/Sep 2009
Veronique de Rugy |
Destroying Jobs in Order to Save Them: Obama's Corporate Tax "Reforms" Make a Bad Situation Worse. Instead of making the corporate tax system worse, why not reform it? Why not avoid old protectionist tricks such as Buy American provisions and instead let U.S. firms compete abroad without the chains of the U.S. tax code? |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
CFO
July 1, 2002
Tim Reason |
Love It and Leave It? Will the outcry over inversions change the way overseas income is taxed? |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
Chemistry World
March 10, 2015
Anmdrew Turley |
AbbVie to buy Pharmacyclics for pipeline boost AbbVie has agreed to buy US biotech Pharmacyclics for $21 billion in a bid to re-stock its pipeline. |
The Motley Fool
February 26, 2007
Brian Lawler |
Shire's Busy Week Shire Pharmaceuticals announces year-end results, new regulatory approval, and another acquisition. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Chemistry World
May 26, 2015
Phillip Broadwith |
Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt. |
Pharmaceutical Executive
August 1, 2013
William Looney |
Succinctly Shire: An Interview with CEO Flemming Ornskov Shire's new CEO has a simple strategy for success: Set the pace on specialty medicines, spread the positive buzz and momentum of a growth stock, and seize the opportunity to innovate. |
The Motley Fool
October 9, 2007
Brian Lawler |
Shire Slims Down, Slightly The U.K.-based pharmaceutical sells off some of its marketed drugs in order to focus more on its key ADHD franchises. |
Chemistry World
November 4, 2015
Phillip Broadwith |
Shire to buy cardiovascular specialist Dyax The deal gives Shire access to Dyax's portfolio of approved and developmental drugs for treating hereditary angioedema. |
